• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4851128)   Today's Articles (54)
For: Nilsson FOL, Asanin ST, Masters ET, Iadeluca L, Almond C, Cooper M, Smith S. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden. Pharmacoeconomics 2021;39:941-952. [PMID: 34080140 PMCID: PMC8298221 DOI: 10.1007/s40273-021-01015-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 03/06/2021] [Indexed: 05/03/2023]
Number Cited by Other Article(s)
1
Farinasso CM, Ferreira VL, Medeiros FC, da Rocha AP, Parreira PDCS, Oliveira LA, Marra LP, Lucchetta RC, de Oliveira HA. Matching-Adjusted Indirect Comparison Studies in Oncology: A Scoping Review Focused on Reporting Quality. Value Health Reg Issues 2025;47:101088. [PMID: 39999561 DOI: 10.1016/j.vhri.2025.101088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2024] [Revised: 11/10/2024] [Accepted: 12/17/2024] [Indexed: 02/27/2025]
2
Shang Y, Guo H. Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Expert Rev Pharmacoecon Outcomes Res 2024:1-6. [PMID: 39508823 DOI: 10.1080/14737167.2024.2421389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2024] [Accepted: 10/19/2024] [Indexed: 11/15/2024]
3
Liu W, Huo G, Chen P. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer. Front Public Health 2024;12:1213318. [PMID: 38435286 PMCID: PMC10906082 DOI: 10.3389/fpubh.2024.1213318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Accepted: 02/05/2024] [Indexed: 03/05/2024]  Open
4
Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, Soto J. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. CLINICOECONOMICS AND OUTCOMES RESEARCH 2023;15:659-671. [PMID: 37701861 PMCID: PMC10494862 DOI: 10.2147/ceor.s415711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Accepted: 08/15/2023] [Indexed: 09/14/2023]  Open
5
Chayab L, Konstantelos N, Leighl NB, Tadrous M, Wong WWL. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). PHARMACOECONOMICS 2023:10.1007/s40273-023-01279-2. [PMID: 37268866 DOI: 10.1007/s40273-023-01279-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Accepted: 05/02/2023] [Indexed: 06/04/2023]
6
Naik J, Beavers N, Nilsson FOL, Iadeluca L, Lowry C. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2023;21:661-672. [PMID: 37173513 DOI: 10.1007/s40258-023-00807-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 03/26/2023] [Indexed: 05/15/2023]
7
Smith S, Albuquerque de Almeida F, Inês M, Iadeluca L, Cooper M. Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2023;26:64-70. [PMID: 35985941 DOI: 10.1016/j.jval.2022.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 06/29/2022] [Accepted: 07/07/2022] [Indexed: 06/15/2023]
8
Baba K, Goto Y. Lorlatinib as a treatment for ALK-positive lung cancer. Future Oncol 2022;18:2745-2766. [PMID: 35787143 DOI: 10.2217/fon-2022-0184] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]  Open
9
Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Lowry C, Tzanetakos C, Kourlaba G. Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece. JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH 2022;9:50-57. [PMID: 35620456 PMCID: PMC8853822 DOI: 10.36469/jheor.2022.32983] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 01/18/2022] [Indexed: 06/04/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA